Aeglea BioTherapeutics Investor Presentation Deck

JNJ's VEGA study demonstrated power of combination therapy despite relative weakness of components VEGA COMBINATION STUDY (N=71/ARM) -A+22% 25% Anti-TNF (Golimumab) BLACK BOX WARNING ~additive absolute clinical remission rates (induction) 24% Anti-IL23 (Guselkumab) 47% 22% 25% Combination | PROBABLE BLACK BOX NOTE: In VEGA, only guselkumab (IL-23) was continued in maintenance for the combo arm in a treat-through design; Spyre plans to use combinations in maintenance. Maintenance remission rates for the anti-TNF arm, anti-IL23 arm, and induction combination arm were 28%, 31%, and 48%, respectively.; Feagan, B. G. et al. Lancet Gastroenterol. Hepatol. 8, 307-320 (2023). SPYRE 30

View entire presentation